Navigation Links
KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema
Date:8/23/2011

inhibition and its potential as a new approach to treating DME have created a significant opportunity. We believe that in KalVista we have put in place all the necessary scientific, clinical and drug discovery and development expertise, and sufficient funding, to capitalize on this opportunity and create a highly differentiated and valuable company."

Andrew Crockett, KalVista's CEO, said: "I am delighted that KalVista has garnered substantial financial support from leading life sciences investors Novo A/S and SV Life Sciences to fund this exciting new business. We have an ambitious target to become a leading company focused on the development of novel treatments for DME and believe we have the team, the expertise, the assets and the approach to achieve this goal."

About KalVista Pharmaceuticals

KalVista is a new ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.

KalVista's founders include world-leading experts in diabetic retinopathy, Dr Lloyd Paul Aiello, Professor of Ophthalmology at Harvard Medical School and Director of the Joslin's Beetham Eye Institute, and Dr Edward Feener, Associate Professor of Medicine at Harvard Medical School and Joslin Diabetes Center. In addition to this therapeutic expertise, KalVista has a management team with proven experience in bringing small molecules through the clini
'/>"/>

SOURCE KalVista Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
(Date:8/3/2015)... Silver Spring, MD (PRWEB) , ... August 03, 2015 , ... ... announce the addition of a new associate podiatrist, creating the largest medical practice in ... in foot and ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American Medical Association show ... in their lives. Often time, low back and sciatic pain can happen as a ... managed clinically with powerful pain medication or spinal surgery. Dynamic Health Care in ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... the supportive muscles and connective tissues of a woman’s pelvic organs (uterus, ... damage include straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... ... medical students are in “a trending profession” that comprises a growing percentage of ... needed the most. , That was one part of the message delivered by ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
Breaking Medicine News(10 mins):Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Local Retail Advocate Wins National Recognition 2
... 30 (HealthDay News) -- Genes affect hereditary coronary heart disease ... study. While it,s long been known that hereditary factors ... due to genes or unhealthy lifestyle in the family, the ... the investigators examined the health records of 80,214 adopted men ...
... It,s not how old but how frail patients are that can ... fact, young patients in poor health may have worse outcomes than ... the University of Michigan Comprehensive Cancer Center finds that patients with ... spread to distant parts of the body. These findings ...
... found that climate change may lead to more asthma-related health ... the next decade. The data, published in the current ... changing levels of ozone could lead to a 7.3 percent ... The research team, led by Perry Sheffield, ...
... 2011Despite recent concerns that changes in atmospheric pressure during ... via pump devices, the current evidence is limited and ... are available, according to an insightful editorial in ... by Mary Ann Liebert, Inc. The editorial is available ...
... by extroverted college students and their less socially inclined peers ... on partying and drinking to be happy and more on ... positive thinking. "You don,t have to go out ... they need to do, particularly when they,re new to campus," ...
... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) -- Swedish ... seems to be a harbinger of an increased risk of ... strongly tied to the inflammatory processes that are central to ... of the new study, published online Aug. 30 in the ...
Cached Medicine News:Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News: Happiness: All in who you know, goals 2Health News:Blood Protein Might Signal Death Risk in Elderly 2
... FSH EIA Test is based ... solid phase enzyme-linked immunosorbent assay. ... monoclonal anti-FSH for solid phase ... anti-alpha FSH in the antibody-enzyme ...
Lyophilized, tri-level assayed human serum-based control, Low, intermediate and high levels, Lot-specific target values provided, Suitable for use with RIA, EIA and chemiluminescent,methodo...
... Hormone (FSH) is intimately involved in the ... of the gonadal tissues, which synthesize and ... The levels of circulating FSH is controlled ... feedback relationship. The FSH Quantitative Test ...
Complete product line for typing all classical HLA loci including A, B, C DRA, DRB1, DRB3, DRB4, DRB5, DQA, DQB1, DPA1, and DPB1....
Medicine Products: